Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.
LATEST NEW HAMPSHIRE ANGLE
Fosters: Is it just a messaging problem?
Prosecution of female continues in prostitution case in which police 'lack evidence' to charge male